REGN - Spark Newswire

1 minute read

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $606

September 7, 8:21 AM

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $576 to $606.

REGN

5 minute read

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab

By Shanthi Rexaline

September 2, 8:19 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)

ABBV

5 minute read

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical

By Shanthi Rexaline

August 31, 8:05 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)

ABSI

1 minute read

Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential

By Vandana Singh

August 30, 3:55 PM

Mayo Clinic and nference are jointly conducting artificial intelligence-powered studies evaluating monoclonal antibodies for COVID-19 in patients with an elevated risk of requiring hospitalization.

LLY

1 minute read

Pfizer’s Abrocitinib Beats Dupixent Late-stage Eczema Trial

By Vandana Singh

August 30, 10:59 AM

Pfizer Inc (NYSE:PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ:SNY) – Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent…

PFE

1 minute read

Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis

By Vandana Singh

August 30, 6:58 AM

A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe…

REGN

3 minute read

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration

By Shanthi Rexaline

August 27, 7:35 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)

AGEN

7 minute read

Stocks That Hit 52-Week Highs On Thursday

By Benzinga Insights

August 26, 10:02 AM

Before 10 a.m. ET on Thursday, 91 companies hit new 52-week highs.

1 minute read

Fauci Says Monoclonal Antibody COVID-19 Treatments Is Being Under-Utilized, Recommends Utilizing It To Fullest

By Bill Haddad

August 24, 2:03 PM

-Reuters

GMAB

1 minute read

Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration

By Vandana Singh

August 24, 12:57 PM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related macular…

BAYRY

Feed Symbols: REGN